bioAffinity Technologies, Inc. (BIAF) Form 424B5 — Nov 2, 2026
bioAffinity Technologies filed a 424B5 prospectus supplement on November 2, 2026, increasing its at-the-market offering capacity by $3,428,226, bringing the total registered under the supplement to $5,228,226 of common stock. The company has already sold 114,672 shares for approximately $1.3 million gross under its May 2025 ATM sales agreement with WallachBeth Capital, and sold $4 million of stock in the prior twelve months under the small-issuer (I.B.6) cap.
Key figures
- Gross Proceeds
- 1300000
- Offering Price
- at-the-market pricing; last reported sale price $2.91 on 2026-10-30
- Shares Offered
- up to $5,228,226 of common stock registered under this supplement; $3,428,226 additional ATM capacity
- Shares Outstanding
- 1813011
- Ib6 12mo sales
- $4,000,000
- Additional atm capacity
- $3,428,226
- Non affiliate market value
- $27,684,678
- Reference price sept 4 2026
- $15.27
- Shares sold under sales agreement
- 114672
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.